Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Dr. Reddy’s Laboratories Ltd. ( (IN:DRREDDY) ) just unveiled an announcement.
Dr. Reddy’s Laboratories has clarified that a recent media report stating it is still awaiting a major near-term trigger is accurate, confirming it has not yet received Health Canada’s final approval, or Notice of Compliance, for its Semaglutide Injection. The company disclosed that it has obtained Drug Identification Numbers for the product as part of the regulatory review and continues to work with the regulator, while emphasizing that there is currently no undisclosed material information, no ongoing negotiations related to the article, and no material impact from the news on its operations, despite recent price volatility prompting proactive regulatory disclosures.
Management reiterated that it complies with disclosure requirements under SEBI Listing Regulations and makes prompt announcements when events are deemed material. By addressing the exchange’s query and the market’s reaction, Dr. Reddy’s signaled that the Canadian Semaglutide opportunity remains pending regulatory clearance and that current developments do not yet constitute a trigger requiring additional market-sensitive disclosure.
More about Dr. Reddy’s Laboratories Ltd.
Dr. Reddy’s Laboratories Ltd. is a global pharmaceutical company based in India, operating in the generic and branded drug segments. The company develops, manufactures, and markets a range of pharmaceutical products across key therapeutic areas, with a growing focus on regulated markets such as North America and other international geographies.
Average Trading Volume: 58,526
Technical Sentiment Signal: Buy
Current Market Cap: 1018.4B INR
For an in-depth examination of DRREDDY stock, go to TipRanks’ Overview page.